Celltrion, a global leader in biopharmaceuticals, has announced its acquisition of iQone Healthcare Switzerland, a specialized pharmaceutical company focused on distribution, sales, and marketing in Switzerland.
The acquisition, expected to be finalized by the fourth quarter of 2024, marks a significant milestone in Celltrion’s European expansion strategy. Once finalized, iQone Healthcare Switzerland will operate as a fully owned subsidiary under Celltrion Healthcare Hungary Kft. The deal will also grant Celltrion access to in-house licensing opportunities, further strengthening its pipeline of innovative therapies.
Tae-Hyun Ha, Celltrion’s Vice President and Head of Europe, highlighted the significance of this acquisition, saying: “This marks a major turning point in our growth approach. After building strong direct sales networks, we are now focusing on acquisitions to fast-track our expansion across Europe. With a distribution network covering over 20 regions, we are well-equipped to thrive in the highly competitive biosimilar pharmaceutical market.”
He added: “Celltrion operates as a fully integrated company, overseeing every aspect of the value chain—from R&D and manufacturing to sales, marketing, and distribution. This seamless integration allows us to maintain and grow a reliable supply of top-quality biosimilar medications. In Switzerland, we aim to strengthen our market presence and portfolio further. This acquisition underscores our commitment to operational excellence and continuous innovation at the local level.”
Laurent Massuyeau, the Founder and Chairman of iQone Healthcare Switzerland, shared his enthusiasm for the acquisition, stating: “Our strong partnership with Celltrion over the past decade has created an excellent foundation for this integration. Combining Celltrion’s expertise in product development with our robust commercial operations, this acquisition will drive growth and improve access to essential and groundbreaking biosimilar medicines across Switzerland.
“Remaining true to our core values and backed by the ‘iQone for You’ program—a specialized service package designed for healthcare professionals in the Swiss market—we will continue to serve our clients with flexibility and efficiency, quickly delivering new treatment options to Switzerland.”